A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2017
Price : $35 *
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 May 2015, as reported by ClinicalTrials.gov.